Shilpa Medicare signs manufacturing deal with NXI Therapeutics
pharmafile | May 12, 2026 | News story | Manufacturing and Production | Shilpa Medicare
Shilpa Medicare has entered into a long-term development and manufacturing agreement with Swiss biotech company NXI Therapeutics focused on an immunomodulatory programme.
Under the agreement, Shilpa will provide chemistry, manufacturing and controls (CMC) development, process scale-up, GMP clinical supply and commercial manufacturing support from early development through to potential commercialisation.
The companies said the collaboration reflects growing demand for outsourcing partnerships in biologics and specialty therapeutics, particularly within autoimmune and immune-modulation programmes.
Financial terms of the agreement were not disclosed, although the companies said the deal includes milestone-linked expansion opportunities and could develop into a longer-term commercial supply arrangement if clinical and regulatory milestones are achieved.
The agreement marks the third named partnership announced by Shilpa Medicare within the past year as the company continues to expand its contract development and manufacturing organisation (CDMO) operations.
Vishnukanth Bhutada, Managing Director of Shilpa Medicare, said the agreement supported the company’s strategy of positioning itself as a long-term development and manufacturing partner for biotech companies.
He continued: “Our integrated development and commercial manufacturing capabilities enable us to support complex assets across the full product lifecycle. We continue to see strong momentum in high-value biologics and specialty therapeutics, strengthening long-term growth visibility for our CDMO platform.”
NXI Therapeutics Chief Executive Ruben Herrendorff commented that the agreement made use of the partners’ respective strengths.
“Shilpa’s scientific depth, quality systems, and scalable GMP manufacturing capabilities make them an ideal partner as we advance our immunomodulatory program toward clinical and commercial milestones,” he explained.
Demand for CDMO support has continued to increase as biotech companies seek external expertise in development, manufacturing and scale-up activities, particularly for complex biologic therapies.
Related Content
Shilpa Medicare and Orion partner, expanding into European market
Shilpa Biocare, a wholly owned subsidiary of Shilpa Medicare, has signed a commercial supply agreement …
